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nance. It also brings us to the inter-
secting paths of self-renewal and cell 
survival. Indeed, the direct compari-
son of ESC and HSC self-renewal and 
survival programs will require a more 
complete characterization of their 
respective components.
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How insulin-secreting β cells of the pancreas communicate with each other is largely 
unknown. In this issue of Cell, Konstantinova et al. (2007) show that the signaling proteins 
EphA and ephrin-A modulate insulin secretion, providing fresh insights into the functional 
significance of the clustering of β cells, which occurs in islets.The regulation of metabolic processes 
requires that cells communicate with 
their neighbors to ensure an appro-
priate response to the changing envi-
ronment. The pancreas is a classic 
example of a tissue that depends on 
intercellular communication among 
the same (autocrine) and/or differ-
ent (paracrine) cell types. The human 
pancreas is composed of over a mil-
lion islets, each islet comprising sev-
eral thousand cells including prima-
rily insulin-secreting β cells but also 
glucagon-secreting α cells, somato-
statin-secreting δ cells, pancreatic 
polypeptide-secreting (PP) cells, and 
ghrelin-producing ε cells. Within each 
islet, the different endocrine cells 
are thought to communicate with 
each other, either extracellularly via 
secreted products or directly through 
cell junctions. A role for paracrine and autocrine communication in the regu-
lation of islet secretory function was 
proposed decades ago (Halban et al., 
1982). For instance, insulin release 
from β cells can act on α cells to influ-
ence glucagon secretion, and soma-
tostatin from δ cells acts as a para-
crine inhibitor of neighboring α and 
β cells (Bonner-Weir and Orci, 1982; 
Samols and Stagner, 1990). Although 
intercellular exchange between β 
cells through membrane channels 
was confirmed by electrophysiologic 
and metabolic coupling experiments, 
the proteins and signaling mecha-
nisms that underlie the communica-
tion between these insulin-secreting 
cells remain unclear. In this issue, 
Konstantinova et al. (2007) reveal that 
signaling via an ephrin ligand and its 
Eph receptor mediate communica-
tion between β cells.Cell 129Receptor tyrosine kinases (RTKs) 
play an important role in communi-
cating crucial information from the 
environment to the inside of the cell 
to modulate fundamental cellular 
processes. The Eph receptors consti-
tute the largest family of RTKs, and, 
together with their plasma membrane-
bound ephrin ligands, have multiple 
functions during development and 
adulthood. Ephrins are divided into 
two subclasses: the A-subclass lig-
ands (ephrin-A1 through ephrin-A5) 
are tethered to the cell membrane 
by a glycosylphosphatidylinositol 
anchor, whereas the B-subclass lig-
ands (ephrin-B1 through ephrin-B3) 
have a transmembrane domain fol-
lowed by a short cytoplasmic region 
(Kullander and Klein, 2002).
In contrast with most RTKs, the 
Eph family possesses a unique fea-, April 20, 2007 ©2007 Elsevier Inc. 241
ture in that signaling can 
originate from either the 
ephrin ligands (termed 
reverse signaling) or from 
the Eph receptors (termed 
forward signaling). This 
bidirectional signaling has 
emerged as an impor-
tant signature function by 
which Ephs and ephrins 
can control output sig-
nals, especially in proc-
esses requiring cell-to-cell 
communication. The Eph-
ephrin system plays an 
important role in neuronal 
development and func-
tion, processes requir-
ing precise cell migra-
tion to allow appropriate 
neuronal connections via 
cell-to-cell communica-
tion and secretory events 
in synapses. Perhaps it 
should not be surprising, 
therefore, that pancreatic 
β cells, which share neu-
ral ancestry, also use the 
Eph-ephrin system for 
their secretory function.
Konstantinova et al. 
(2007) provide evidence 
that the Eph-ephrin sys-
tem may form an impor-
tant pathway for cell-to-
cell communication in the 
regulation of insulin secre-
tion (Figure 1). The authors 
observed the expression 
of both A and B classes of 
ephrins and Ephs—with an 
abundance of EphA and 
ephrin-A—in both mouse 
and human islets. The 
authors built on this ini-
tial observation by using 
immunohistochemistry to 
demonstrate that ephrins 
and Ephs are expressed 242 Cell 129, April 20, 2007 ©2figure 1. ephA and ephrin-A Modulate Insulin secretion in 
Pancreatic β cells
Insulin secretion from pancreatic β cells is largely dependent on am-
bient glucose concentration. EphA forward signaling and ephrin-A 
reverse signaling inhibit and promote insulin secretion, respectively 
(Konstantinova et al., 2007). In the presence of glucose, EphA (blue) 
is dephosphorylated and ephrin-A (green) reverse signaling predomi-
nates, thereby promoting insulin secretion by an as yet unknown 
mechanism. β cells also communicate with each other and neighbor-
ing α cells through the action of secreted insulin on insulin receptors. 
Question marks indicate potential crosstalk between Eph-ephrin sign-
aling and the insulin receptor tyrosine kinase (yellow) for communica-
tion within and between insulin-secreting β cells and glucagon-secret-
ing α cells. PTP, phosphotyrosine phosphatase.007 Elsevier Inc.insulin secretion (Li et al., 
2004). Interestingly, Rac1 
was found to be activated 
by ephrin-A5 reverse signal-
ing and inhibited by EphA5 
forward signaling, consist-
ent with opposing effects 
of EphA5 and ephrin-A5 on 
glucose-stimulated insulin 
secretion.
G l u c o s e - s t i m u l a te d 
insulin secretion relies on 
the metabolism of glucose 
by glycolysis and the tricar-
boxylic acid cycle (TCA) to 
generate ATP. An increase 
in ATP closes ATP-sensi-
tive K+ channels, which in 
turn depolarizes the plasma 
membrane, thus opening 
voltage-gated L-type Ca2+ 
channels and facilitat-
ing insulin secretion. How 
does Eph-ephrin mediate 
the effects of glucose on 
insulin secretion? Konstan-
tinova et al. (2007) found 
that shortly after glucose 
stimulation, EphA5 phos-
phorylation decreased in 
both islets and MIN6 β 
cells. This modification alle-
viated the inhibitory effects 
of EphA5 forward signaling 
on insulin secretion. Thus, 
under basal conditions, 
EphA forward signaling 
suppressed insulin secre-
tion, and at high glucose 
concentrations, dephos-
phorylation of EphA causes 
the ephrin reverse signaling 
to be favored, thereby pro-
moting insulin secretion. In 
this scenario, it is not clear 
whether the glucose-stim-
ulated dephosphorylation 
of EphA5 involves the acti-
vation of a specific protein in areas of cell-cell contact, but 
not on free surfaces of insulinoma-
derived MIN6 β cells. Subsequently, 
using fusion protein ligands that can 
activate ephrin-A5 (EphA5-Fc) or 
EphA5 (ephrin-A5-Fc) signalling, the 
authors demonstrated that ephrin-
A5 reverse signaling promoted and 
EphA5 forward signaling inhibited glucose-stimulated insulin secre-
tion, and these effects were depend-
ent on β cells being in contact with 
each other.
Studies in other cell types indicate 
that EphA-ephrin-A signaling targets 
the small GTPase Rac1, which is 
known to regulate F-actin remodeling 
and to modulate glucose-stimulated tyrosine phosphatase, and how this 
modification modulates insulin secre-
tion is also unknown. Furthermore, 
given that most of the experiments in 
this report have used an insulinoma-
derived β cell line, it will be impor-
tant to confirm these mechanisms 
in intact human islets. A logical next 
step would be to evaluate the physi-
ological significance of the Ephs and 
ephrins in insulin secretion in vivo by 
creating and characterizing β cell-
specific inducible knockouts of spe-
cific Ephs and/or ephrins. It is notable 
that EphA5 is localized to the insulin 
secretory granule, an organelle that 
is also associated with ATP-depend-
ent K channels, glucokinase, and the 
insulin receptor (Geng et al., 2003; 
Hribal et al., 2003). Whether the close 
association between these proteins 
is necessary for intracrine regulation 
at the level of the secretory granule is 
worth investigating.
Glucose-stimulated insulin release 
typically occurs in two phases—a 
rapid first phase (2–3 min in the 
mouse and 10 min in humans) after 
glucose stimulation and a pro-
longed second phase that lasts up 
to 30 min. In contrast to many fac-
tors—such as the insulin receptor 
tyrosine kinase—that regulates the 
first phase glucose-induced insu-
lin release (Kulkarni et al., 1999), A number of molecules have been 
discovered that can inhibit the entry 
of HIV-1 and other viruses into cells 
of their host (reviewed in Dimitrov, 
2004; Liu et al., 2007). Perhaps 
the most well-known are the anti-
HIV peptides SJ-2176 (Jiang et al., 
1993) and T20 (Wild et al., 1994) 
derived from the C-terminal heptad 
repeat region of the viral envelope 
glycoprotein gp41. T20 remains the 
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Although human blood plasm
identity is largely unknown. M
portion of α1-antitrypsin that p
hydrophobic segment of the vEph-ephrin signaling predominantly 
affects the second phase of insulin 
release. Another avenue to pursue is 
whether there might be interaction 
between these two RTK systems 
that both regulate β cell function and 
insulin secretion.
Although a part of the mystery 
underlying β cell-to-β cell commu-
nication has been unraveled, the 
relevance of these observations to 
disease needs clarification. Could 
abnormalities in the expression 
of Ephs and ephrins contribute to 
defects in altered insulin secretion 
or maintenance of β cell mass that 
are characteristic of type 2 diabetes 
or other insulin-resistant states? Are 
there polymorphisms in the genes 
that code for Ephs and ephrins that 
are associated with altered glucose 
homeostasis in humans? Further 
integrative studies should help define 
the functions of Ephs and ephrins 
and their role in diabetes and meta-
bolic diseases.Cell 12
only HIV-1 entry inhibitor approved 
for clinical use by the US Food and 
Drug Administration. The search 
for peptides with similar or greater 
potency and crossreactivity and 
improved pharmacokinetics has yet 
to yield additional peptide-based 
therapeutics of clinical utility. Fol-
lowing the example of T20, research 
has remained largely focused on 
peptides derived from viruses. How-
sticky fingers
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ever, human blood plasma contains 
naturally occurring low-molecular-
weight protein inhibitors of HIV-1 
infection. Although the possibility of 
finding inhibitory peptides in human 
blood plasma has long been recog-
nized, until recently the task of iden-
tifying them from a mixture of more 
than one million different peptides 
and small proteins has been daunt-
ing. Now, using a peptide library 
 of HIV-1
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